Alumis' ONWARD3 Data Reinforce Efficacy but Do Not Alter Valuation Risk

What happened

Alumis announced new data from the ONWARD3 long-term extension showing envudeucitinib rapidly and durably improved psoriasis burden across scalp, itch, and quality of life, with 54% of patients achieving complete skin clearance (PASI 100) at Week 48. Patients who switched from placebo or apremilast after the initial 52-week period achieved responses comparable to those on continuous treatment, indicating flexibility in treatment sequencing. These results build on the previously reported ONWARD1 and ONWARD2 data, which had already positioned envudeucitinib as a potential leading oral therapy. However, the announcement does not address the key competitive disadvantages highlighted in prior analysis, notably twice-daily dosing versus once-daily rivals such as Takeda's zasocitinib and J&J's icotrokinra, nor does it provide new long-term safety data beyond the 48-week cut. The company reiterated its plan to submit an NDA in Q4 2026, but the market may have already priced in approval and strong commercial uptake given the stock's elevated valuation.

Implication

The ONWARD3 results reinforce envudeucitinib's clinical profile and support a smooth NDA filing, yet they do not mitigate the fundamental concerns that led to a 'POTENTIAL SELL' rating on ALMS. Twice-daily dosing remains a practical disadvantage against once-daily competitors, and the absence of new long-term safety data leaves open the risk of label restrictions or boxed warnings. The upcoming NDA submission in Q4 2026 is a critical milestone, but the real value driver will be the label content and early commercial adoption, which are uncertain given payer pressure and entrenched rivals. The Q3 2026 lupus Phase 2b readout also looms as a binary event that could either validate the multi-indication thesis or remove a significant portion of implied franchise value. With the stock trading well above the attractive entry level of $17 and a crowded bullish consensus, investors should trim into strength or wait for a more favorable entry point or evidence of durable differentiation.

Thesis delta

The thesis remains unchanged: this new data confirm envudeucitinib's efficacy but do not resolve the competitive and safety overhangs that justify a cautious stance. The previous recommendation to trim above $28 and seek entry near $17 remains appropriate, as the market reaction may be muted given already high expectations. If anything, the data reinforce that the primary risks are commercial execution and differentiation, not efficacy, so the risk-reward has not improved materially.